

SEQUENCE LISTING

<110> CHAIN, Daniel G.

<120> RECOMBINANT ANTIBODIES SPECIFIC FOR BETA-AMYLOID ENDS,
DNA ENCODING AND METHODS OF USE THEREOF

<130> CHAIN1B

<140> 00

<141> 1999-10-12

<150> PCT/US98/06900

<151> 1998-04-09

<150> 60/041,850

<151> 1997-04-09

<160> 8

<170> PatentIn Ver. 2.0

<210> 1

<211> 59

<212> PRT

<213> Homo sapiens

<400> 1

Glu	Val	Lys	Met	Asp	Ala	Glu	Phe	Arg	His	Asp	Ser	Gly	Tyr	Glu	Val
1				5				10						15	

His	His	Gln	Lys	Leu	Val	Phe	Phe	Ala	Glu	Asp	Val	Gly	Ser	Asn	Lys
		20						25						30	

Gly	Ala	Ile	Ile	Gly	Leu	Met	Val	Gly	Gly	Val	Val	Ile	Ala	Thr	Val
		35					40						45		

Ile	Val	Ile	Thr	Leu	Val	Met	Leu	Lys	Lys	Lys
		50					55			

<210> 2

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:HUMAN PEPTIDE

WITH ARTIFICIAL TERMINAL CYSTEINE RESIDUE

<400> 2

Asp Ala Glu Phe Arg Cys

1

5

<210> 3

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:HUMAN PEPTIDE
WITH ARTIFICIAL TERMINAL CYSTEINE RESIDUE

<400> 3

Asp Ala Glu Phe Arg His Asp Cys

1

5

<210> 4

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:HUMAN PEPTIDE
WITH ARTIFICIAL TERMINAL CYSTEINE RESIDUE

<400> 4

Cys Leu Met Val Gly Gly Val Val

1

5

<210> 5

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:HUMAN PEPTIDE
WITH ARTIFICIAL TERMINAL CYSTEINE RESIDUE

<400> 5

Cys Val Gly Gly Val Val Ile Ala

1

5

<210> 6
<211> 6
<212> PRT
<213> Homo sapiens

<400> 6
Asp Ala Glu Phe Arg His
1 5

<210> 7
<211> 13
<212> PRT
<213> Homo sapiens

<400> 7
Glu Ile Ser Glu Val Lys Met Asp Ala Glu Phe Arg His
1 5 10

<210> 8
<211> 4
<212> PRT
<213> Homo sapiens

<400> 8
Glu Phe Arg His
1

<210>9

<211>6

<212> PRT

<213> Artificial Sequence>

<220>

<223> Description of Artificial Sequence: HUMAN PEPTIDE

<400>9

Glu Val His His Gln Cys

1

5

<210> 10

<211> 12

<212> PRT

<213> Artificial Sequence>

<220>

<223> Description of Artificial Sequence: HUMAN PEPTIDE

<400> 10

Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln

1

5

10

<210> 11

<211> 8

<212> PRT

<213> Artificial Sequence>

<220>

<223> Description of Artificial Sequence: HUMAN PEPTIDE

<400> 11

Cys-Gly-Gly-Val-Val-Ile-Ala-Thr

1

5

<210> 12
<211> 14
<212> PRT
<213> Artificial Sequence>
<220>
<223> Description of Artificial Sequence: HUMAN PEPTIDE
<400> 12

Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val

1 5 10

<210> 13
<211> 14
<212> PRT
<213> Artificial Sequence>
<220>
<223> Description of Artificial Sequence: HUMAN PEPTIDE
<400>

Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala-Thr

1 5 10

<210>9

<211>6

<212> PRT

<213> Artificial Sequence>

5 <220>

<223> Description of Artificial Sequence: HUMAN PEPTIDE

<400>9

Glu Val His His Gln Cys

10 1 5

<210> 10

<211> 12

15 <212> PRT

<213> Artificial Sequence>

<220>

<223> Description of Artificial Sequence: HUMAN PEPTIDE

<400> 10

20

Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln

1 5 10

25 <210> 11

<211> 8

<212> PRT

<213> Artificial Sequence>

<220>

30 <223> Description of Artificial Sequence: HUMAN PEPTIDE

<400> 11

Cys-Gly-Gly-Val-Val-Ile-Ala-Thr

1 5

<210> 12

<211> 14

<212> PRT

5 <213> Artificial Sequence>

<220>

<223> Description of Artificial Sequence: HUMAN PEPTIDE

<400> 12

10 Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val

1

5

10

<210> 13

15 <211> 14

<212> PRT

<213> Artificial Sequence>

<220>

<223> Description of Artificial Sequence: HUMAN PEPTIDE

20 <400>

Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala-Thr

1

5

10